By pairing powerful third-party solutions such as Transposagen’s piggyBac system with our world-class gene design expertise and industry-leading gene synthesis, DNA2.0 can ensure that our customers have the competitive edge.
Menlo Park, CA (PRWEB) May 24, 2012
DNA2.0, the leading bioengineering solutions provider, today introduced the piggyBac™ Mammalian Expression System, an efficient, one plasmid method to create stable transfectants in mammalian cells. Licensed from Transposagen Biopharmaceuticals Inc., the piggyBac transposon system includes reversible genetic modification and rapid insertion site characterization. DNA2.0 scientists have taken Transposagen’s best-in-class genetic modification system and optimized it for the company’s all-in-one pHULK vectors. Applications range from stem cell research to protein production and cell line engineering.
“At DNA2.0, our chief goal is to provide our customers with the best possible tools to move from idea to experimental results quickly and efficiently,” said Claes Gustafsson, cofounder and Chief Commercial Officer of DNA2.0. “By pairing powerful third-party solutions such as Transposagen’s piggyBac system with our world-class gene design expertise and industry-leading gene synthesis, DNA2.0 can ensure that our customers have the competitive edge.”
DNA2.0’s piggyBac vectors are the first to come with CometGFP™, a green fluorescent protein for easy confirmation of transfection, protein production or cellular localization. pHULK piggyBac mammalian expression vectors are available as catalog items and for custom cloning for synthetic genes. Like all DNA2.0 products, pHULK vectors are manufactured at the company’s state-of-the-art facility in Menlo Park, California and never outsourced to countries with lax IP protection. DNA2.0 customers maintain full rights to their intellectual property.
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit http://www.DNA20.com.